Preclinical Evaluation Identifies EGT710 as an Oral Inhibitor Targeting SARS-CoV-2 Main Protease

Researchers have conducted a preclinical evaluation of EGT710, an oral non-peptidomimetic reversible covalent inhibitor targeting the SARS-CoV-2 main protease (Mpro). The study focused on assessing the compound’s potential as a therapeutic agent against COVID-19 by analyzing its biochemical properties, antiviral activity, and pharmacokinetic profile. The findings indicate that EGT710 effectively inhibits the Mpro enzyme, which plays a critical role in viral replication.

The study detailed how EGT710 demonstrated potent inhibition of SARS-CoV-2 Mpro in vitro. Researchers observed that the compound exhibited strong antiviral activity across multiple cell-based assays. Additionally, pharmacokinetic analysis revealed favorable oral bioavailability and metabolic stability in preclinical models. These characteristics suggest that EGT710 could be a promising candidate for further development as an oral treatment option for COVID-19. Further studies will likely aim to evaluate its safety and efficacy in clinical trials.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 28, 2025

Related posts:

GSK Acquires Boston Pharmaceuticals’ Liver Disease Assets, Expanding Portfolio AI Model Developed at Charité Detects Over 170 Cancer Types to Aid High-Risk Diagnoses House Hearing Explores AI’s Role in Drug Development, Medicare Management, and Mental Health Care Systems Thinking Applied to Analyze Complexities in Abortion Policy Agenda Setting

Author

GOAI